Kenvue Inc. (KVUE)
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
The European Commission—the EU's executive arm—said that the sale fully addresses officials' earlier concerns that the deal could hinder competition in tampon markets in Czechia, Estonia, and Slovakia.
Market Concentration Is Spooking Wall Street—I'm Buying Kenvue
While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and the reasoning might make you rethink your own
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?
Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) pays a quarterly dividend of $1.28 per share. That is an annualized forward rate of $5.12 and a yield of 5.16%.
Kimberly-Clark's 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal
Kimberly-Clark just raised its dividend for the 54th straight year while simultaneously chasing a nearly $50 billion acquisition, and income investors are now weighing whether a deal of that size can coexist with a payout that costs over $1.
Kenvue's Brand Strength and Innovation Strategy Support Growth
KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.
Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?
Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.
Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead
KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.
Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment
Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands in the country to address competition concerns.
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects
KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.
Kimberly-Clark: Temporary Headwinds, Strong Innovation And Kenvue Synergies Support A Buy
Kimberly-Clark is rated Buy, supported by a strong innovation pipeline, international growth, and upside from the Kenvue acquisition. KMB faces transient headwinds in North America and China, but these are expected to abate, with management forecasting mid- to high-single-digit EPS CAGR from 2026–2028. The Kenvue deal will initially dilute EPS, but synergy realization is tracking ahead of plan, with $1.9B cost and $1.4B revenue synergy targets.
KVUE Q2 Earnings Miss Estimates as Margins Narrows, Sales Rise
Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.
